SMG8 is a regulatory component of the nonsense-mediated mRNA decay (NMD) pathway, which eliminates transcripts containing premature stop codons essential for mammalian development and stress response 1. SMG8 functions as part of the SMG1C complex alongside SMG1 kinase and SMG9, where it inhibits SMG1 kinase activity through a C-terminal kinase inhibitory domain (KID) that covers the catalytic pocket 1. SMG8 and SMG9 form a conserved G-domain heterodimer that interacts with SMG1; nucleotide hydrolysis of SMG9 triggers conformational changes allowing SMG8's KID to release from the inhibitory position, restoring SMG1 kinase activity for UPF1 phosphorylation 12. Despite structural importance, SMG8 and SMG9 function as nonessential modulators that safeguard NMD efficiency; their complete loss causes only modest NMD impairment but renders cells hypersensitive to SMG1 inhibition 3. Biallelic SMG8 loss-of-function variants cause Alzahrani-Kuwahara syndrome (ALKUS), a neurodevelopmental disorder featuring global developmental delay, microcephaly, facial dysmorphism, and congenital heart and eye malformations 45. SMG8 variants are also emerging as subtype-specific risk factors for frontotemporal lobar degeneration 6. Additionally, SMG8/SMG9 deficiency promotes resistance to ATR inhibitors in gastric cancer through altered DNA damage response mechanisms 7.